NCL makes significant progress during the past year

September 2006
Chemical Business;Sep2006, Vol. 20 Issue 9, p64
Trade Publication
The article highlights the accomplishments of the Pune, India-based National Chemical Laboratory (NCL) in 2005. The average impact factor per scientific paper published by NCL was 2.067, which has been increasing since 2003. The laboratory was granted 31 Indian patents and 29 U.S. patents. NCL has licensed a catalytic process to produce Epichloroydrin to Aditya Biria Group. NCL has an external cash flow of Rs21.5 crore at the close of the financial year.


Related Articles

  • Mastering new skills. Breithaupt, Holger // EMBO Reports;Apr2005, Vol. 6 Issue 4, p301 

    This article presents information about lab management courses for group leaders in scientific researches. Being a group leader is probably one of the hardest and most challenging jobs the natural sciences have to offer. Therefore, funding organizations, such as the HHMI and the Burroughs...

  • Unigene to Announce First Quarter 2011 Financial Results on May 9 2011.  // Biomedical Market Newsletter;5/5/2011, p259 

    The article offers information on the development of Unigene Laboratories Inc., the leader in the design, delivery, manufacture and development of peptide-based therapeutics in Boonton, New Jersey. It mentions the announcement of the company to host a conference call and live audio webcast to...

  • Method for producing aqueous liquor dyeable modified polypropylene threads and the use thereof.  // Chemical Fibers International;Oct2003, Vol. 53 Issue 5, p322 

    DITF of Germany has patented in 2003 a method for producing aqueous liqour dyeable modified polypropylene threads, characterized in that CR-polypropylene suitable for fiber formation is mixed with a reaction partner which can react with the CR-polypropylene and the obtained mixture is processed...

  • Production of dimensionally stable polyester yarns.  // Chemical Fibers International;Oct2003, Vol. 53 Issue 5, p322 

    Zimmer AG has patented in 2003 an invention that relates to a method for producing stretched multifilament polyester applications such as tires, cord, conveyor belts and the like. According to the inventive method, chips or granules having a so-called textile grade are post-condensed in a...

  • Method for producing synthetic threads form polymer mixtures.  // Chemical Fibers International;Oct2003, Vol. 53 Issue 5, p323 

    Zimmer AG has patented in 2003 a method for producing synthetic threads from a polymer mixture consisting of polyamide, which serves as a base polymer, and of at least one additive polymer, whereby the polymer mixture in the form of a polymer melt is forced through nozzle openings at specific...

  • Mouse patent sparks 'uncivil' spat. Abbott, Alison // Nature;6/4/2009, Vol. 459 Issue 7247, p620 

    The article focuses on the patent dispute between the two nonprofit research institutes, Jackson Laboratory and Central Institute for Experimental Animals (CIEA), over the right on a strain of immunodeficient mice. The CIEA claimed that Jackson Laboratory has infringed the patent of its...

  • SWOT Analysis.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p36 

    The article presents an overview of Forest Laboratories Inc., a pharmaceutical company in the U.S. that develops and markets ethical drug products and over-the-counter products. The company was expected to have strong revenues from its products Lexapro and Namenda, which allows it to pursue...

  • HUMIRA: BEST TO MARKET. Comer, Ben // Pharmaceutical Executive;Feb2012, Vol. 32 Issue 2, p32 

    The article focuses on the success of the inflammation drug Humira from the Abbot Laboratories Inc. In 2011, the company reported a growth rate of 21.1 percent for Humira globally, with 7.9 billion dollars in total sales. Pharmaceutical executives promoted Humira as a drug with strong long-term...

  • A Mixed Bag for Dr Reddy's.  // BioSpectrum;Jul2014, Vol. 12 Issue 7, p86 

    The article analyzes the performance of Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. in 2013. Topics include its investment for product development, the investigational new drug (IND) application it filed in the U.S. for its proposed biosimilar rituximab and the launch of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics